JP7446322B2 - アルツハイマー病を治療する方法 - Google Patents

アルツハイマー病を治療する方法 Download PDF

Info

Publication number
JP7446322B2
JP7446322B2 JP2021547654A JP2021547654A JP7446322B2 JP 7446322 B2 JP7446322 B2 JP 7446322B2 JP 2021547654 A JP2021547654 A JP 2021547654A JP 2021547654 A JP2021547654 A JP 2021547654A JP 7446322 B2 JP7446322 B2 JP 7446322B2
Authority
JP
Japan
Prior art keywords
hydroxypropyl
cyclodextrin
composition
human patient
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509358A5 (cg-RX-API-DMAC7.html
JP2022509358A (ja
Inventor
フリノウ,シャロン,エイチ
テイト,ジェフリー,エル.
ファイン,エヌ.,スコット
Original Assignee
シクロ セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シクロ セラピューティクス インク filed Critical シクロ セラピューティクス インク
Publication of JP2022509358A publication Critical patent/JP2022509358A/ja
Publication of JP2022509358A5 publication Critical patent/JP2022509358A5/ja
Application granted granted Critical
Publication of JP7446322B2 publication Critical patent/JP7446322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2021547654A 2018-10-29 2019-10-24 アルツハイマー病を治療する方法 Active JP7446322B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862752131P 2018-10-29 2018-10-29
US62/752,131 2018-10-29
US201962885053P 2019-08-09 2019-08-09
US62/885,053 2019-08-09
PCT/US2019/057784 WO2020092107A1 (en) 2018-10-29 2019-10-24 Methods for treating alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2022509358A JP2022509358A (ja) 2022-01-20
JP2022509358A5 JP2022509358A5 (cg-RX-API-DMAC7.html) 2022-10-28
JP7446322B2 true JP7446322B2 (ja) 2024-03-08

Family

ID=68583503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547654A Active JP7446322B2 (ja) 2018-10-29 2019-10-24 アルツハイマー病を治療する方法

Country Status (10)

Country Link
US (3) US11925659B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873604B1 (cg-RX-API-DMAC7.html)
JP (1) JP7446322B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084480A (cg-RX-API-DMAC7.html)
CN (1) CN112996562A (cg-RX-API-DMAC7.html)
BR (1) BR112021008139A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114021C (cg-RX-API-DMAC7.html)
ES (1) ES2992137T3 (cg-RX-API-DMAC7.html)
PT (1) PT3873604T (cg-RX-API-DMAC7.html)
WO (1) WO2020092107A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016276774A1 (en) 2015-06-10 2018-01-18 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11466008B2 (en) 2017-09-18 2022-10-11 Eip Pharma, Llc Co-crystals of neflamapimod (VX-745)
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
AU2021284155A1 (en) * 2020-06-02 2023-01-05 National University Of Singapore Compositions, their uses in therapy and methods thereof
WO2022051631A1 (en) 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
CA3200988A1 (en) * 2020-11-06 2022-05-12 John Jahangir Alam Treatment of gait dysfunction in neurodegenerative disease
WO2022099094A1 (en) * 2020-11-06 2022-05-12 Eip Pharma, Inc. Compositions and methods for treating depression
WO2022197640A1 (en) * 2021-03-14 2022-09-22 Massachusetts Institute Of Technology Apoe4 impairs myelination via altered cholesterol biosynthesis and transport in neuronal cells
EP4433828A1 (en) * 2021-11-18 2024-09-25 Vib Vzw Improved gamma-secretase inhibitor screening assays
JP2025506676A (ja) 2022-02-18 2025-03-13 ベレン セラピューティクス ピー.ビー.シー. ヒドロキシプロピル-ベータ-シクロデキストリンの組成物及びその精製方法
WO2023191425A1 (ko) * 2022-03-28 2023-10-05 주식회사 비엔에이치리서치 약물의 전기생리학적 스크리닝 방법
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
KR20250024808A (ko) * 2022-06-13 2025-02-19 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린 제조를 위한 시스템 및 방법
CA3263540A1 (en) * 2022-07-29 2024-02-01 Anavex Life Sciences Corp. Compositions and methods for the prevention of cognitive decline caused by degenerative diseases
US20260124236A1 (en) * 2022-09-30 2026-05-07 Cyclo Therapeutics, Inc. Methods for treating early alzheimer’s disease
WO2025214478A1 (zh) * 2024-04-12 2025-10-16 北京华昊中天生物医药股份有限公司 一种优替德隆药物组合物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500310A (ja) 2013-12-13 2017-01-05 ロケット フレールRoquette Freres Hdlコレステロール値を上昇させることによって疾病を治療かつ/または予防する、メチルシクロデキストリンをベースとする組成物
JP2017517528A (ja) 2014-06-12 2017-06-29 ユニバーシティ オブ ノートルダム デュ ラック 神経疾患および大脳損傷の処置のための組成物および方法
US20180085392A1 (en) 2015-04-17 2018-03-29 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス, インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US8883494B2 (en) 2003-11-14 2014-11-11 Adil A. KHAN In vitro model for neuronal death
KR101530050B1 (ko) 2007-03-02 2015-06-22 주식회사 노브메타파마 알츠하이머 질환 및 치매를 치료하기 위한 조성물 및 방법
WO2013155485A2 (en) 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin
CA2880880C (en) 2012-08-03 2021-01-26 John Mckew Cyclodextrin for the treatment of lysosomal storage diseases
EP3432880A4 (en) * 2016-03-20 2019-12-11 Asdera LLC USE OF CYCLODEXTRINS TO REDUCE ENDOCYTOSIS IN MALIGNES AND NEURODEEGENERATIVE DISEASES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500310A (ja) 2013-12-13 2017-01-05 ロケット フレールRoquette Freres Hdlコレステロール値を上昇させることによって疾病を治療かつ/または予防する、メチルシクロデキストリンをベースとする組成物
JP2017517528A (ja) 2014-06-12 2017-06-29 ユニバーシティ オブ ノートルダム デュ ラック 神経疾患および大脳損傷の処置のための組成物および方法
US20180085392A1 (en) 2015-04-17 2018-03-29 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス, インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AUTOPHAGY,2018年,14(7),pp.1129-1154
Free Radical Biology and Medicine,2018年,120,S79, P-114
http://dx.doi.org/10.5772/intechopen.71970[検索日:2023年9月6日],2017年
Human Molecular Genetics,2017年,26(5),pp.843-859
IRYO,71(3),2017年,pp.132-137
J. Exp. Med.,2013年,209(13),pp.2501-2513
Journal of Drug Targeting,2009年,17(2),pp.168-179
Journal of Pharmaceutical Sciences,2016年,105,pp.2372-2380
Molecules,2016年,21,1748 (22 pages)
Phys. Chem. Chem. Phys.,2016年,18,pp.20476-20485

Also Published As

Publication number Publication date
ES2992137T3 (es) 2024-12-09
US20240415871A1 (en) 2024-12-19
EP3873604A1 (en) 2021-09-08
US11925659B2 (en) 2024-03-12
BR112021008139A2 (pt) 2021-08-03
CA3114021A1 (en) 2021-05-07
JP2022509358A (ja) 2022-01-20
EP3873604B1 (en) 2024-08-21
WO2020092107A1 (en) 2020-05-07
PT3873604T (pt) 2024-10-22
CA3114021C (en) 2025-05-27
US20220008453A1 (en) 2022-01-13
KR20210084480A (ko) 2021-07-07
CN112996562A (zh) 2021-06-18
US20250302864A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
US11925659B2 (en) Methods for treating Alzheimer's disease
HK1242998A1 (zh) 治疗法布里病的给药方案
EP3445369B1 (en) Vx-745 for use in the treatment of dementia
KR20250078929A (ko) 알츠하이머병 치료를 위한 면역치료법과 사일로이노시톨 병용
EP3137097B1 (en) Treatment and prevention of alzheimer's disease (ad)
CN120051284A (zh) 用于治疗早期阿尔茨海默病的方法
WO2020214538A1 (en) Treatment and prevention of dementia and other neurodegenerative diseases
EP4209222A1 (en) Treatment and prevention of alzheimer's disease (ad)
AU2015254663B2 (en) Treatment and prevention of Alzheimer's Disease (AD)
HK40059055B (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
HK40059055A (en) Methods for treating alzheimer's disease with hp-[beta]-cyclodextrin
CA3268619A1 (en) Methods for treating early alzheimer's disease
US20240016783A1 (en) Riluzole for the treatment of alzheimer's disease
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
Sharma et al. Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases
US20200289473A1 (en) Methods of treating neurodegeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240227

R150 Certificate of patent or registration of utility model

Ref document number: 7446322

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150